Efficacy and Safety of Sofosbuvir/Vipatavir Combined with Ribavirin in Treatment of Genotype 3 Patients with Chronic Hepatitis C

Zhi-rong ZHAO; Hai-wen LI; Xiao-fei LI; Ni-hong LU; Yong-rui YANG

doi:10.12259/j.issn.2095-610X.S20210325

Volume 42 Issue 3

Apr. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2021 > 42(3): 98-103

Zhi-rong ZHAO, Hai-wen LI, Xiao-fei LI, Ni-hong LU, Yong-rui YANG. Efficacy and Safety of Sofosbuvir/Vipatavir Combined with Ribavirin in Treatment of Genotype 3 Patients with Chronic Hepatitis C[J]. Journal of Kunming Medical University, 2021, 42(3): 98-103. doi: 10.12259/j.issn.2095-610X.S20210325

Citation:

Zhi-rong ZHAO, Hai-wen LI, Xiao-fei LI, Ni-hong LU, Yong-rui YANG. Efficacy and Safety of Sofosbuvir/Vipatavir Combined with Ribavirin in Treatment of Genotype 3 Patients with Chronic Hepatitis C[J]. Journal of Kunming Medical University, 2021, 42(3): 98-103. doi: 10.12259/j.issn.2095-610X.S20210325

Citation:

Zhi-rong ZHAO, Hai-wen LI, Xiao-fei LI, Ni-hong LU, Yong-rui YANG. Efficacy and Safety of Sofosbuvir/Vipatavir Combined with Ribavirin in Treatment of Genotype 3 Patients with Chronic Hepatitis C[J]. Journal of Kunming Medical University, 2021, 42(3): 98-103. doi: 10.12259/j.issn.2095-610X.S20210325

PDF( 630 KB)

Efficacy and Safety of Sofosbuvir/Vipatavir Combined with Ribavirin in Treatment of Genotype 3 Patients with Chronic Hepatitis C

doi: 10.12259/j.issn.2095-610X.S20210325

Zhi-rong ZHAO^{1, 2},
Hai-wen LI¹,
Xiao-fei LI¹,
Ni-hong LU^{1
,
,},
Yong-rui YANG^{1
,
,}

1.
Dept. of Hepatology，The 3rd People’s Hospital of Kunming Yunnan Provincial Center for Infectious Diseases Clinical Medicine），Kunming Yunnan 650041
2.
School of Public Health，Dali University，Kunming Yunnan 671000，China

Received Date: 2020-12-01
Publish Date: 2021-04-09

Abstract

Abstract

Objective To observe the efficacy and safety of combined with Ribavirin （SOF/VEL+RBV） in the treatment of genotype-3 patients with chronic hepatitis C. Methods We selected 80 genotype-3, and newly treated chronic hepatitis C patients, who were admitted to the Department of Liver Diseases, Kunming Third People's Hospital, and divided them into 2 groups. The combined treatment group, containing 40 patients, was treated with the antiviral therapy that combines Sofosbuvir/Velpatasvir and Ribavirin （SOF/VEL + RBV）. The control group was 40 patients that were adopted with a single-agent antiviral treatment of Sofosbuvir/Velpatasvir. All patients were monitored with their continuous virological response, the changes in biochemical indicators and Fibroscan indicators during the treatment of 4 and 12 weeks as well as an additional 12 weeks after stopping the therapy. Results The combined treatment group showed their SVR rate at the 4^th and 12^th week were 90.00%, 70.00% and 97.50%, 80.00%, respectively and reached 97.50%, 80.00%, at 12^th week after the termination of the treatment. The patients' serum biochemical indicators such as ALT, AST, GGT, and ALB decreased more significantly than the patients in the single-agent group （P < 0.05） and there was no significant difference between the two groups at the 12-week follow-up after the treatment termination （P > 0.05）. For the single-agent group, at the 12th week after the treatment the Fibroscan value decrease significantly （F = 5.700, P = 0.018） and at 12th-week follow-up after the treatment termination there was no difference in Fibroscan values between the two groups （F = 0.012, P = 0.912）. During the period of the treatment time, the adverse reactions from both groups were mainly fatigue, headache and dizziness. Conclusions For genotype-3 patients with newly treated chronic hepatitis C, the combined treatment of Sofosbuvir/Velpatasvir and Ribavirin （SOF/VEL + RBV） can have higher SVR rate and biochemical response rate, better efffect on improving liver fibrosis with better safety than single-agent treatment of Sofosbuvir/Velpatasvir.
- Chronic hepatitis C,
- Sofosbuvir/Velpatasvir,
- Efficacy; Safety

FullText(HTML)

References(16)

References

[1]	杨婉汝. 云南地区HCV基因型流行特征及耐药突变基因检测方法的初步建立[D]. 昆明: 昆明理工大学硕士论文, 2019.
[2]	中华医学会肝病学分会,中华医学会感染病学分会. 丙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志,2019,35(12):2670-2686.
[3]	陈仲丹. 全球丙型肝炎消除的进展、挑战及应对[J]. 中华肝脏病杂志,2020,28(10):812-816. doi: 10.3760/cma.j.cn501113-20200929-00539
[4]	罗楠,毛志鹏. 昆明市2013—2017年丙型病毒性肝炎流行特征及趋势分析[J]. 中国卫生产业,2020,17(5):188-189.
[5]	孔毅,许琳,康文玉,等. 云南省1959-2014年病毒性肝炎流行特征分析[J]. 中国卫生统计,2016,33(4):657-659.
[6]	Wei Lai, Xie Qing, Huang Yan, 等. 索磷布韦/维帕他韦用于基因1-6型HCV中国患者时的安全性和疗效: 来自一项3期临床试验的结果[C]. 第十届全国疑难及重症肝病大会, 苏州, 2019.
[7]	von Felden,Vermehren,Ingiliz,et al. High efficacy of sofosbuvir velpatasvir and impact of baseline resistance‐associ[J]. Alimentary Pharmcolgy Therapeutics,2018,7(4):1288-1295.
[8]	刘立,李俊义,刘春云,等. 索非布韦联合达拉他韦治疗基因3型慢性丙型肝炎的疗效和安全性研究[J]. 中国病毒病杂志,2018,8(5):384-388.
[9]	刘立,李俊义,杜映荣,等. 索非布韦/达拉他韦加利巴韦林治疗丙型肝炎肝硬化的疗效及安全性[J]. 肝脏,2018,23(7):587-590. doi: 10.3969/j.issn.1008-1704.2018.07.010
[10]	付小义,金娴,徐晓婧,等. 泛基因型DAA治疗慢性丙型肝炎[J]. 新发传染病电子杂志,2018,3(1):30-33. doi: 10.3877/j.issn.2096-2738.2018.01.008
[11]	Struble Kimberly,Chan-Tack Kirk,Qi Karan,et al. Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype:U. S. Food and Drug Administration’ s evaluation[J]. Hepatology,2018,67(2):482-491. doi: 10.1002/hep.29601
[12]	郭明哲. 丙型肝炎病毒复制子新型构建方法的及因3a、6a型病毒株耐药性的研究[D]. 北京: 中国科学院大学博士论文, 2019.
[13]	黄纪亮. 索非布韦联合维帕他韦治疗慢性丙型肝炎的疗效及安全性: 系统评价与Meta分析[D]. 广州: 暨南大学硕士论文, 2018.
[14]	Hall,Jenkins,Hulgan,et al. Hepatitis C Coinfection and Mortality in People Living with HIV in Middle Tennessee[J]. AIDS Res Hum Retroviruses,2020,36(3):193-199. doi: 10.1089/aid.2019.0113
[15]	Johnson,Thompson,Raccor. Hepatitis C Virus-Genotype 3:Update on Current and Emergent Therapeutic Interventions[J]. Curr Infect Dis Rep,2017,19(6):22. doi: 10.1007/s11908-017-0578-5
[16]	李志恒,崔燕,李晓霞,等. HCV/HIV合并感染者肝功能和机体免疫功能的研究[J]. 医学动物防制,2021,37(1):1-4.

Relative Articles(20)

Relative Articles

[1]	Xiuzhen ZHANG, Canyan HU, Lei CAI. Analysis of the Application Effect of Bicyclol Combined with Ganciclovir in the Treatment of EB Virus-Related Infectious Mononucleosis in Children Based on Liver Function，IgA，IgM，and IgG Levels. Journal of Kunming Medical University, 2024, 46(): 1-6.
[2]	Xiaohua LU, Hongxin YUAN. The Analysis of the Correlation between BTLA，CTLA-4 Gene Polymorphisms and the Efficacy and Prognosis of TACE Combined Targeted Therapy for Liver Cancer. Journal of Kunming Medical University, 2023, 44(9): 126-135. doi: 10.12259/j.issn.2095-610X.S20230927
[3]	Kang HUANG, Zhirong ZHAO, Haiwen LI, Ti WU, Ting JIA, Lu WANG, Nihong LU, Yongrui YANG. Efficacy and Safety of Sofosbuvir/Velpatasvir with or without Ribavirin in Cirrhotic Patients with Genotype 3 Chronic Hepatitis C Infection. Journal of Kunming Medical University, 2023, 44(11): 126-134. doi: 10.12259/j.issn.2095-610X.S20231119
[4]	Yanwen XU, Xin WANG, Hua JIANG, Chenchen LIANG, Li LIU, Shenghao LI, Jianpeng GAO. Efficacy and Safety of Sofosbuvir-based Drugs for the Treatment of Patients with Chronic Hepatitis C Genotype 3： A Single Centre Real-world Retrospective Analysis. Journal of Kunming Medical University, 2022, 43(11): 124-129. doi: 10.12259/j.issn.2095-610X.S20221115
[5]	Xue-song LI, Yun XIA, Zhen WANG, Hao ZOU, Lin-hai HE, Lin WANG. Application of PTGD Combined with Elective LC in the Treatment of Cholecystolithiasis with Acute Onset of Chronic Cholecystitis. Journal of Kunming Medical University, 2021, 42(12): 95-100. doi: 10.12259/j.issn.2095-610X.S20211226
[6]	Yong-rui YANG, Hai-wen LI, Zhi-rong ZHAO, Lu WANG, Ting JIA, Zhi-jian DONG, Xiao-fei LI, Ni-hong LU. Clinical Efficacy and Safety of Sofosbuvir and Vipatavir in the Treatment of Patients with Chronic Hepatitis C and HCV/HIV co-infection. Journal of Kunming Medical University, 2021, 42(7): 130-136. doi: 10.12259/j.issn.2095-610X.S20210722
[7]	Zhi-rong ZHAO, Hai-wen LI, Ni-hong LU, Ling SHEN, Xiao-fei LI, Yong-rui YANG. A Clinical Study on the Use of Propofol Tenofovir in the Treatment of Chronic Hepatitis B. Journal of Kunming Medical University, 2021, 42(1): 89-93. doi: 10.12259/j.issn.2095-610X.S20210141
[8]	Li-xian YUAN, Hong-tao ZHANG, Rui LI, Kun-rui CHEN, Kun-qian CHEN, An-shu XU. Diagnostic Efficacy of Serum PIVKA-Ⅱ Detection in Primary Hepatocellular Carcinoma. Journal of Kunming Medical University, 2020, 41(12): 80-84. doi: 10.12259/j.issn.2095-610X.S20201223
[9]	Zhao Li Dong . Clincal Effect of Different Doses of Esomeprazole in Treatment of Acute Nonvariceal Upper Gastrointestinal Bleeding. Journal of Kunming Medical University,
[10]	Jin Ying . The Short-term and Long-term Clinical Effect of Leep Knife Treatment of Chronic Cervicitis. Journal of Kunming Medical University,
[11]	Hu Wei Hua . The Observation of Clinical Effect of Using Ambroxol in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Journal of Kunming Medical University,
[12]	Zeng Hai Ping . . Journal of Kunming Medical University,
[13]	Ma Yan Li . . Journal of Kunming Medical University,
[14]	Li Hai Feng . . Journal of Kunming Medical University,
[15]	Yang Yong Rui . . Journal of Kunming Medical University,
[16]	Liu Jin Hong . . Journal of Kunming Medical University,
[17]	Li Jia Xiang . . Journal of Kunming Medical University,
[18]	Guo Xian Li . . Journal of Kunming Medical University,
[19]	. . Journal of Kunming Medical University,
[20]	Yang Xi Yun . . Journal of Kunming Medical University,